November 11th, 2026Identifying Which Patients With HCC Need Immunotherapy Before Liver TransplantNeil Mehta, MD, and Laura Kulik, MD, discussed which patients with HCC awaiting liver transplant may benefit from bridging immunotherapy.Read more
November 9th, 2026Comparing Liver Cancer Prevention Strategies in Japan and the USAt The Liver Meeting 2026, Ryosuke Tateishi, MD, PhD, discussed what the US and Japan can learn from each other to prevent liver cancer.Read more
November 22nd, 2026Bringing Bispecifics and Clinical Trials to Community SCLC PracticesAnne Chiang, MD, PhD, discusses how community practices can deliver bispecifics, monitor for CRS, and offer trials for patients with SCLC.Read more
November 21st, 2026Rethinking HCC Surveillance and Treatment Amid a Shifting Risk Landscape“This is the closest we have been to biomarkers replacing ultrasound,” said Amit G. Singal, MD, MS, FAASLD.Read more
November 21st, 2026Sequencing B7-H3 and SEZ6 ADCs With DLL3 Bispecifics in SCLCADCs directed towards B7-H3, SEZ, DLL3, and TROP2 appear to be “super exciting,” according to Anne Chiang, MD, PhD.Read more
November 20th, 2026Efti Plus Pembrolizumab and RT Yields 81% 12-Month DFS in Soft Tissue SarcomaNeoadjuvant eftilagimod alfa, pembrolizumab, and radiotherapy produced an 81.1% 12-month DFS rate in high-risk, resectable soft tissue sarcoma.Read more
November 20th, 2026Tarlatamab Maintenance Leads the Leaps Forward in Small Cell Lung CancerAnne Chiang, MD, PhD, discusses DeLLphi-305 and other leaps forward in small cell lung cancer, along with a setback regarding lurbinectedin.Read more
November 20th, 2026Younger, Fitter AML Populations May Not Need Intensive ChemotherapyAmir T. Fathi, MD, explains which assumptions about frontline AML treatment are ready to be challenged in the field.Read more